about
Noninvasive monitoring of radiation-induced treatment response using proton magnetic resonance spectroscopy and diffusion-weighted magnetic resonance imaging in a colorectal tumor model.Dynamic (18) F-FDG PET for Assessment of Tumor Physiology in Two Breast Carcinoma XenograftsLongitudinal magnetic resonance imaging-based assessment of vascular changes and radiation response in androgen-sensitive prostate carcinoma xenografts under androgen-exposed and androgen-deprived conditionsNeoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging.Monitoring the effect of targeted therapies in a gastrointestinal stromal tumor xenograft using a clinical PET/CT.Early changes in apparent diffusion coefficient predict the quantitative antitumoral activity of capecitabine, oxaliplatin, and irradiation in HT29 xenografts in athymic nude mice.MRI volumetry for prediction of tumour response to neoadjuvant chemotherapy followed by chemoradiotherapy in locally advanced rectal cancerRadiotherapy for spinal metastases from breast cancer with emphasis on local disease control and pain response using repeated MRIPrincipal component analysis for the comparison of metabolic profiles from human rectal cancer biopsies and colorectal xenografts using high-resolution magic angle spinning 1H magnetic resonance spectroscopy.Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer.Hypoxia-independent gene expression signature associated with radiosensitisation of prostate cancer cell lines by histone deacetylase inhibition.Associations between tumor vascularization assessed by in vivo DCE-MRI and the presence of disseminated tumor cells in bone marrow in breast cancer patients at the time of diagnosis.Intermittent and continuous imatinib in a human GIST xenograft model carrying KIT exon 17 resistance mutation D816H.Individual tumor volume responses to short-course oxaliplatin-containing induction chemotherapy in locally advanced rectal cancer - Targeting the tumor for radiation sensitivity?Inhibitory effects of oxaliplatin in experimental radiation treatment of colorectal carcinoma: does oxaliplatin improve 5-fluorouracil-dependent radiosensitivity?Oxaliplatin-containing Preoperative Therapy in Locally Advanced Rectal Cancer: Local Response, Toxicity and Long-term Outcome.Routine pelvic MRI using phased-array coil for detection of extraprostatic tumour extension: accuracy and clinical significance.The tumour hypoxia marker pimonidazole reflects a transcriptional programme associated with aggressive prostate cancer.Early prediction of response to radiotherapy and androgen-deprivation therapy in prostate cancer by repeated functional MRI: a preclinical study.Multimodal functional imaging for early response assessment in GIST patients treated with imatinib.Preclinical dynamic 18F-FDG PET - tumor characterization and radiotherapy response assessment by kinetic compartment analysis.Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study.Establishment and characterization of a human gastrointestinal stromal tumour (GIST) xenograft in athymic nude mice.Artificial neural networks for prediction of response to chemoradiation in HT29 xenografts.Dynamic (18)F-FDG-PET for monitoring treatment effect following anti-angiogenic therapy in triple-negative breast cancer xenografts.Diffusion-weighted magnetic resonance imaging of rectal cancer: tumour volume and perfusion fraction predict chemoradiotherapy response and survival.Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer.Markers of Mitochondrial Metabolism in Tumor Hypoxia, Systemic Inflammation, and Adverse Outcome of Rectal CancerHigh tumor glycine concentration is an adverse prognostic factor in locally advanced rectal cancerLocalization of radio-recurrence within the prostate: anti-3-18F-FACBC PET/CT compared with multiparametric MRI using histopathology as reference standardHigh level of circulating vitamin D during neoadjuvant therapy may lower risk of metastatic progression in high-risk rectal cancerDW MRI for evaluation of treatment response to imatinib in a rectal gastrointestinal stromal tumourDiffusion-weighted magnetic resonance imaging for pretreatment prediction and monitoring of treatment response of patients with locally advanced breast cancer undergoing neoadjuvant chemotherapyMR-guided simultaneous integrated boost in preoperative radiotherapy of locally advanced rectal cancer following neoadjuvant chemotherapyCombined MR Imaging of Oxygen Consumption and Supply Reveals Tumor Hypoxia and Aggressiveness in Prostate Cancer PatientsSex-related differences in primary metastatic site in rectal cancer; associated with hemodynamic factors?Toward Personalized Computer Simulation of Breast Cancer Treatment: A Multiscale Pharmacokinetic and Pharmacodynamic Model Informed by Multitype Patient DataImmunogenic cell death by neoadjuvant oxaliplatin and radiation protects against metastatic failure in high-risk rectal cancerPTEN Expression in Prostate Cancer: Relationship With Clinicopathologic Features and Multiparametric MRI FindingsLocal failure is a dominant mode of recurrence in locally advanced and clinical node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy
P50
Q31133162-F3975CF8-6BA8-4F0C-9E76-97B02BF5106EQ33669980-B1A89CC0-7AAA-4904-B823-2DC0AF001C92Q34177229-86079BD6-C29A-4CF1-A9B9-5B912AEA3169Q34940150-2A2DB22C-F0FE-4E11-93E9-1AAC5B3F6B22Q35535875-CA416470-4FB0-4325-8043-FBC6A148B84FQ35812742-59EA43AE-5125-4399-8971-868A20076281Q36235746-3FBBFB67-F64C-4650-8361-0AB12C5E6C31Q36491648-B307849D-BC51-4DD6-8A97-A60BD31CE78DQ36649292-11D5318F-73B6-4CFC-8020-55BB5F059AE3Q38485785-DC066727-FA89-4BF7-9468-49DB138D0608Q38748006-1AE6D9DB-C132-4DB1-B601-E9B48B06EC33Q39262277-CBCEC88E-0701-4480-8D95-7EDEEA8DEA0DQ39739341-6AD4C8C6-1858-4994-B3B2-85F4EB31997DQ39927667-3813CAB5-CF7D-4412-BB6A-323206E35C1CQ40051129-F411FCCC-6BFE-4B3F-8021-88D24F490936Q40903862-8DCBE312-D77A-4FE6-B416-17D4AA767F5AQ41063995-4CFB7F58-FCF9-4C3C-8BFF-2A10ADD7DB40Q41740984-9A44FC32-3A98-4F65-A182-1653E27FB88EQ42014353-AF2AE4DB-2557-4308-8C86-8D748664F5B4Q42723805-F2BA1551-9668-48A2-99E5-F5EEE704BD02Q42910924-37EFBFCC-6B3D-4BDB-AD27-BBE2879628C9Q43105772-CE4EA84F-8927-415A-BAB0-D25795998EB4Q43209032-FBBEF445-B51E-4541-9B71-41AAC2746B04Q43279911-481B3F68-8E56-4392-BE6E-ACDD6CD1BB73Q45052401-14B99683-06E0-4335-97F5-EA51C160034EQ52874057-762ACC99-9539-42EC-AF67-69D5272C4CF7Q54114270-31087865-7DBE-4402-A744-C117FFE22CF8Q57067804-DB192617-FD21-4559-933E-47497AE03E0CQ57095431-1C916AA3-94F8-4567-BE97-EADB3E58836CQ58085880-4C6F15CA-2CAC-44DE-9BE5-44C5B0C50E01Q64282678-59193950-5F6B-4560-B017-9386BD6A1C93Q82623474-F66E05B8-92CC-4E3B-9B36-4EA2BA15C0DEQ84071250-6D115607-BA4E-4EB7-9509-19D55311D2C6Q84623256-CA4469CF-C88B-4B75-A09F-7D1EC592EE12Q89266678-B643AB23-ED9B-49B9-BDDA-B41959F05CF1Q92223608-C3F3CB89-0609-4D46-BF52-F4D662BAE186Q92225434-88D67242-255F-4991-B209-1C57EF2F1470Q92360487-C4A1E311-B2D2-4E8B-8360-01E5F09DBBFBQ92477346-171FF3EE-79E2-4DE0-9A73-51A8717A82BFQ93182676-AC7431B1-1C35-428A-AF4E-E62B2D17C63E
P50
description
researcher (ORCID 0000-0002-2579-5298)
@en
wetenschapper
@nl
name
Therese Seierstad
@en
Therese Seierstad
@nl
type
label
Therese Seierstad
@en
Therese Seierstad
@nl
prefLabel
Therese Seierstad
@en
Therese Seierstad
@nl
P31
P496
0000-0002-2579-5298